Preliminary safety, pharmacokinetics, and efficacy of regorafenib, cisplatin, and pemetrexed in patients with advanced non-squamous non-small cell lung cancers

PURPOSE: The addition of bevacizumab, an anti-angiogenesis agent, to cytotoxic chemotherapy improves survival in patients with advanced non-squamous non-small cell lung cancers (nsNSCLCs). Regorafenib is an oral multi-targeted kinase inhibitor with potent anti-angiogenic activity that is approved fo...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Clin Lung Cancer
Huvudupphovsmän: Hellmann, Matthew D, Sturm, Isrid, Trnkova, Zuzana Jirakova, Lettieri, John, Diefenbach, Konstanze, Rizvi, Naiyer A., Gettinger, Scott N.
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2015
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC4750397/
https://ncbi.nlm.nih.gov/pubmed/26003007
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.cllc.2015.04.003
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk